Kahimmune Therapeutics signs exclusive licensing agreement with Gustave Roussy and SATT Paris-Saclay

(MENAFN - ALA Group) –Newly created spin-off of Gustave Roussy and SATT Paris-Saclay specializing in immuno-oncology will exploit hidden genome, also known as dark genome or non-coding genome –It ...